Andrew Selinger, MD
Family Medicine · Bristol, CTNPI 1114937141
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,884 of the $3,309 with a category attached, or 87.2%. It is spread thinly across 26 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 146 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$549
- Lilly USA, LLC$514
- Radiometer America, Inc$425
- AbbVie$312
- Sanofi-aventis U.S. LLC$166
- Exact Sciences$146
- plus $1K from 20 others
Across 13 payments — averaging $2158.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$28K
What the payments were for
- Consulting fees$42513%
- Food & beverage$2,88487%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $549 |
| Lilly USA, LLC | 22 | $514 |
| Radiometer America, Inc | 2 | $425 |
| AbbVie | 16 | $312 |
| Sanofi-aventis U.S. LLC | 9 | $166 |
| Exact Sciences | 6 | $146 |
| Astellas Pharma US Inc | 6 | $128 |
| Johnson & Johnson | 6 | $124 |
| AstraZeneca | 6 | $120 |
| E.r. Squibb & Sons, L.L.C. | 6 | $113 |
| Pfizer | 6 | $109 |
| GSK | 4 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $78 |
| Merck | 4 | $74 |
| Actelion Pharmaceuticals US, Inc. | 2 | $66 |
| Bayer | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Sanofi Pasteur Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Abbott | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Lifescan, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Organon | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hb801$171
How this compares
$3,309 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $86,700 |
| JardianceEmpagliflozin | 80 | $80,413 |
| EliquisApixaban | 33 | $43,122 |
| XareltoRivaroxaban | 25 | $35,756 |
| TrulicityDulaglutide | 26 | $34,078 |
| RybelsusSemaglutide | 15 | $27,006 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,213 |
| FarxigaDapagliflozin Propanediol | 25 | $22,243 |
| JanuviaSitagliptin Phosphate | 16 | $17,006 |
| TradjentaLinagliptin | 24 | $15,116 |
| Nucynta ErTapentadol Hcl | 12 | $12,318 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,906 |
| MyrbetriqMirabegron | 16 | $9,365 |
| Hydromorphone ErHydromorphone Hcl | 13 | $5,585 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $4,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $549 | $113,70690 claims |
| Boehringer IngelheimJardiance, Tradjenta | $20 | $95,529104 claims |
| PfizerEliquis | $109 | $43,12233 claims |
| Johnson & JohnsonXarelto | $124 | $35,75625 claims |
| Lilly USA, LLCTrulicity, Humulin 70-30 | $514 | $34,77538 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $91 | $34,11950 claims |
| AstraZenecaFarxiga | $120 | $22,24325 claims |
| MerckJanuvia | $74 | $17,00616 claims |
| Astellas Pharma US IncMyrbetriq | $128 | $9,36516 claims |
| AbbVieSynthroid | $312 | $1,27715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Bristol
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
- Sanjeev RaoBridgeport$27K
- Michael BeyVernon Rockville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.